Pyrimidinones

• 

  Subject Areas on Research

  • A Small Molecule Pyrazolo[3,4-d]Pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle. 
  • A plant lipocalin promotes retinal-mediated oscillatory lateral root initiation. 
  • Activation mechanism of the mouse cold-sensing TRPM8 channel by cooling agonist and PIP2. 
  • Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. 
  • Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors 
  • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. 
  • Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques. 
  • Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). 
  • Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. 
  • Fluorescent-Linked Enzyme Chemoproteomic Strategy (FLECS) for Identifying HSP70 Inhibitors. 
  • Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. 
  • IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. 
  • In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. 
  • In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. 
  • MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. 
  • Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. 
  • Moving upstream in the war on WNTs. 
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. 
  • Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. 
  • Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma. 
  • Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. 
  • Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. 
  • Single transcriptional and translational preQ1 riboswitches adopt similar pre-folded ensembles that follow distinct folding pathways into the same ligand-bound structure. 
  • Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel. 
  • Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. 
  • The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. 
  • Trametinib (GSK1120212) in the treatment of melanoma. 
  • Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. 
  • Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. 
  • Unraveling the structural complexity in a single-stranded RNA tail: implications for efficient ligand binding in the prequeuosine riboswitch. 
  • Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. 
  • Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway.